



December 11, 2012

PerkinElmer Expands Reagent Portfolio to Accelerate Biotherapeutics Drug Development

New AlphaLISA® no-wash immunoassay kits enable quick and simple detection of drug impurities and toxic effects

WALTHAM, Mass. – December 11, 2012 – [PerkinElmer, Inc.](#), a global leader focused on improving the health and safety of people and the environment, today announced the launch of a new range of [assay kits](#) utilizing AlphaLISA® technology to help improve the safety testing, manufacturing and quality control of biotherapeutic drugs.

Biotherapeutic drug development is a rapidly growing field due to the highly targeted and specific nature of these drugs, which are particularly beneficial for the treatment of patients with cancer, inflammatory disease and rare diseases. Biotherapeutics are naturally occurring molecules, such as antibodies, recombinant proteins and vaccines, and are recognized as an alternative to small-molecule approaches for drug development.

Regulatory requirements addressing potentially harmful side effects and undesirable contaminants that can lead to toxic reactions or adverse immune responses are more stringent for biotherapeutic drugs than for small molecule drugs. PerkinElmer carefully developed these new assays to meet these more stringent performance requirements relating to drug impurities and toxic effects.

“PerkinElmer is continuously seeking new ways to improve human health through the development of innovative technologies,” said Kevin Hrusovsky, President, Life Sciences and Technology, PerkinElmer. “Adverse reactions due to drug toxicity is a real issue that we are passionate about helping to minimize. We are very excited to enable our customers to improve the safety and efficacy of new biotherapeutic drugs being developed through our new assay kits which are the latest addition to our growing biotherapeutics portfolio.”

The kits use PerkinElmer’s [AlphaLISA technology](#) to achieve higher quality results than the comparable ELISA (enzyme-linked immunosorbent assay) technology in half the time, helping to accelerating the drug discovery process. AlphaLISA technology also has a simple protocol with fewer assay steps compared to standard ELISA, resulting in better inter- and intra-assay precision, greatly improved coefficient of variations (CVs), and easier method transfer to downstream departments due to reduced variability.

PerkinElmer has a portfolio of solutions across the biotherapeutics workflow, from target identification, cloning and expression to safety testing and quality control. The portfolio includes the [LabChip® GXII benchtop microfluidic system](#) for high throughput protein analysis and characterization, and the [JANUS® BioTx Pro™ Workstation](#) for protein purification with batch and column chromatography capabilities.

For more information about PerkinElmer’s biotherapeutics solutions, please visit: <http://www.perkinelmer.com/biotherapeutics>

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately \$1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

###

Media Contact:

Paul Barren
Edelman (On behalf of PerkinElmer, Inc.)

Phone: 404-460-9679

Email: paul.barren@edelman.com